Modeling & Simulation Cases
Mechanism-Based PK/PD for Direct Phase III Without Phase II
Proton pump inhibitors have well-defined pharmacological mechanisms. Intragastric pH as PD biomarker correlates closely with clinical endpoints. Mechanism-driven PK/PD models are applied to screen optimal clinical regimens and support Phase II waiver application.
